Growth analysis and gene expression profiling of in vivo GBM xenografts transplanted into rats brain, targeted by CED and IP injection with bevacisumab, cetuximab and both
Kristjan Välk, PhD, Postdoc, University of Bergen, Department of Biomedicine, Jonas Lies vei 91, 5009 Bergen, Norway, Email: Kristjan.firstname.lastname@example.org
Kaarel Krjutskov, PhD, Postdoc, Karolinska Institute, Department of Biosciences and Nutrition, Hälsovägen 7, 14157 Huddinge, Sweden, Email: email@example.com
Jan Bulla, PhD, Professor, University of Bergen Department of Mathematics, Allegaten 41, 5007 Bergen, Norway, Email: firstname.lastname@example.org
Hrvoje Miletic, MD, PhD, Professor, University of Bergen, Department of Biomedicine, Jonas Lies vei 91, 5009 Bergen, Norway, Email: Hrvoje.Miletic@biomed.uib.no
The aim of the current project was to take advantage of GBM rat animal model and treat tumour cells in vivo with bevacisumab and cetuximab- drugs designed to target VEGFR and EGFR pathways. Study consisted of 4 groups: single treatments, combined treatment and control group. For the administration of the drugs the CED (convection enhanced delivery) and IP (intraperitoneal) injection were selected. Axial T1 and T2-weighted RARE sequences of MRI (magnet resonance imaging) were used in order to estimate the tumour size prior and after the treatment.
Upon identification of statistically significant change in tumour volume growth between the different treatment groups the molecular profiling of the biopsy material was conducted.
Quantitative gene expression analysis by the sequencing of mRNA 5′ ends was applied in aim to explore the whole genome level molecular profiles, associated pathways and processes. Immunohistochemistry and western-blot analyses were used for translational level analyses.
The results of the study indicate to the rationale of combinational and targeted treatment on GBM.